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The Watchman (Boston Scientific, Marlbor-
ough, MA, USA) occluder is specifically designed to 
be permanently implanted at or slightly distal to the 
left atrial appendage (LAA) ostia trapping thrombus 
before they exit the LAA. With accumulating proof 
that LAA closure using the Watchman device is 
effective in reducing the risk of thromboembolism 
in patients with atrial fibrillation, it is becoming 
a worldwide predominant occluder. There are 
five different sizes: 21, 24, 27, 30 and 33 mm, and 
are labeled for patients with an LAA ostial diam-
eter between 17 and 31 mm [1]. However, LAA 
anatomy is highly heterogeneous, with a range of 
ostia diameters from 5 to 40 mm [2]. The currently 
available devices are far from ideal, and in some 
patients, the conventional practice of LAA closure 
with a Watchman device could not obtain optimal 
anatomic results, which requires no peri-device 
leakage of clinical significance (> 5 mm) due to 
a suboptimal match between the device and a com-
plex LAA morphology [3]. Therefore, the technical 
challenges of percutaneous LAA occlusion relate 
to the morphology of LAA, including the number 
of lobes, and the maximum and minimum of ostia 
suitable for intervention. An off-label attempt is 
necessary to widen the indication of Watchman in 
a complex LAA anatomy in order to leave no man 
behind. Giant single-lobulated LAA, multilobed 
LAA and small LAA present a real challenge 
for conventional Watchman-based LAA closure. 
Herein, is summarized the latest reports regarding 
Watchman-based technique innovations, focusing 
on patients with off-label LAA anatomy.
A single-device LAA occlusion technique 
concerns the maximum LAA body size suitable 
for intervention. Therefore, in patients with the 
single-lobulated LAA and giant ostia > 31 mm, 
complete closure of the LAA could not be achieved 
with a single Watchman implantation. Clinically 
obvious residual flow > 5 mm in the LAA is associ-
ated with an increasing risk of thromboembolism 
which requires prolonged antithrombotic therapy 
thereby defeating the purpose of an LAA closure 
[4]. Accordingly, adequate closure of this giant LAA 
is essential. In the current issue of the ‘Cardiology 
Journal’ [5], a technology note was published re-
porting three successful attempts using a kissing- 
-Watchman strategy by deploying two Watchman 
devices adjacently in a kissing-fashion to achieve 
complete LAA occlusion in patients with single-
lobulated LAA and giant ostia (> 31 mm). Despite 
a more liberal oversizing technique, favorable 
anatomic results were achieved in all 3 patients. 
Image follow-up showed adequate LAA sealing 
(peri-device leakage < 5 mm), without device-
related thrombosis or obvious device dislocation. 
There were no major adverse events including 
device embolism, pericardial tamponade, stroke/ 
/transient ischemic attack/systemic embolism, 
death or major bleeding during a 1-year clinical 
follow-up. This technical innovation shows that 
a more liberal oversizing technique contributes 
to greater stability rather than a hazard for device 
dislocation and provides a reasonable LAA closure 
strategy in this single-lobulated LAA with giant 
ostia anatomy. 
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Owing to the variations of LAA anatomy, 
in terms of number of lobes, it is impossible to 
completely close LAA with a single Watchman 
device. The LAA uncovered lobe was deemed 
to be a nidus for thrombus formation, because of 
slow blood flow caused by a ridge-like pectinate 
muscle which separates the LAA into two lobes. 
Accordingly, adequate closure may require more 
than a single device in LAA morphology with two 
outgoing lobes. Liu et al. [6] and Jiang et al. [7], 
respectively, reported their initial experience on 
either one-stop or staged double-Watchman im-
plantation. This anatomic structure warranted that 
the two devices were implanted separately rather 
than adjacently, reducing the possibility of direct 
mechanical interaction between the two devices. 
Sealing both the lobes was essential to effectively 
reducing the risk of thrombus formation. According 
to clinical observations and image follow-up, none 
of the patients had severe complications or major 
adverse events. Their reports provide a feasible 
and safe strategy avoiding incomplete LAA closure 
due to a single Watchman implantation in this 
bilobulated-LAA anatomy. 
According to Food and Drug Administration 
labelling, it is recommended in patients with 
a maximal LAA ostial diameter of 17 mm in order 
to accommodate the smallest Watchman device 
(21 mm) currently available for LAA occlusion. 
Deploying a round occluder into a relatively small 
ostium may lead to excessive radial force, which 
could theoretically result in endocardium perfora-
tion or device embolization. Additionally, shoulder 
protrusion of Watchman device out of the LAA may 
interfere with the surrounding structure (circum-
flex coronary artery, mitral valve, pulmonary vein). 
In the issue of ‘Journal of Cardiovascular Electro-
physiology’, Venkataraman et al. [8] reported their 
experience in 31 out of 32 patients with the mean 
maximal LAA ostial width range from 14 mm to 
16 mm who successfully underwent Watchman 
implantation. Although the maximum compression 
ratio was numerically greater than manufacturer 
recommendations (20%) [9], no adverse events 
of clinical significance occurred during a 45 day 
follow-up. Their experience again substantiated 
the fact that over-compression to some extent is 
not a hazard for device dislocation. Additionally, 
moderate shoulder protrusion of the Watchman 
device would not interfere with the surrounding 
structure of LAA. This report provides first-hand 
evidence that Watchman implantation is safe in 
occluding smaller LAA with a maximal LAA ostial 
width < 17 mm.
There is a kaleidoscope of variations concern-
ing LAA anatomy in terms of the diameter of ostia 
and plane of lobes, and no occluder fits them all. 
While those technical innovations can be useful, 
a word of caution should be issued since late me-
chanical interaction is unknown and the number 
of patients and follow-up duration are limited in 
all these reports. More intense imaging follow-up 
may be considered, when dealing with LAAs with 
these complex anatomic features. The authors 
mentioned above should be congratulated for their 
effort in these technical innovations, however, the 
safety and efficacy of these strategies remain to 
be verified by larger cohorts. Nevertheless, these 
technique innovations of LAA closure may over-
come the anatomic limitation and potentially widen 
Watchman-based LAA occlusion indications in all 
candidates for percutaneous LAA closure.
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